While there is a large and growing international literature on economic aspects of biotechnology innovation (for example, work by Carlsson, McKelvey, Orsenigo, Zucker and Darby) these studies concentrate on the United States and Europe. The New Zealand biotechnology industry may be expected to develop along a different trajectory as a consequence of a markedly different set of initial and framework conditions. This paper presents the results of an ongoing study that aims to fill some of the gaps in our knowledge of innovation processes in New Zealand while using the international literature as a benchmark. The size and structure of modern biotech activity in New Zealand is described and compared to other OECD countries using biotech patent data and results from the New Zealand and Canadian biotechnology surveys.
Introduction
Modern biotechnology has the potential to transform large parts of the global economy and to have a major impact on the way we live. Its birth is usually traced back to the development of the recombinant DNA technique in 1973 and hybridoma technology in 1975 (Orsenigo, 1989, p. 37) . The rapid pace and widespread impact of developments in biotechnology since that time has often been referred to as the biotechnology revolution. There is a large and growing international literature on economic aspects of biotechnology innovation which McKelvey (2000) has characterised as "an area of research which attempts to explain how and why the new techniques and knowledge of modern biotechnology can have economic impacts". This paper describes some of the results of an ongoing study that will describe and analyse the innovation system for biotechnology in New Zealand focussing on the major actors and the linkages among them.
The first part of this paper outlines a theoretical framework based on the systems of innovation literature and reviews some key indicators of the effectiveness of New Zealand's national system of innovation (NIS). The size and competitive position of biotech activity in New
Zealand is then described based on data from a variety of sources including the recently completed biotechnology survey and an analysis of biotech patent data. Part 3 presents and analyses data on various factors affecting biotech innovation based on the OECD's Oslo Manual framework. Part 4 draws some conclusions on the state of New Zealand's innovation system for biotechnology.
Definition of Biotechnology
The term biotechnology was coined in 1919 by Karl Ereky, a Hungarian agricultural economist to refer to "all the lines of work by which products are produced from raw materials with the aid of living organisms" (Bud, 1989, p. 10) . Since then "the word biotechnology has been redeveloped at least four times and its definition changed on each occasion" (Kennedy, 1991, p. 218) and in recent years has become increasingly synonymous with genetic modification (GM).
For reasons explained above, the economics literature has tended to focus on modern biotechnology defined in this paper to include GM and modern biotech processes; namely (1) recombinant DNA technology, (2) use of antibodies (3) protein engineering (4) novel bioprocessing techniques (Eliasson and Eliasson, 1997, p. 145, U.S. Congress, 1991, p. 5 ).
The term "modern" is used to distinguish processes that have been developed in the last 30 years or so, from traditional biotech areas such as fermentation and extraction.
The Systems of Innovation Framework
This study uses the Systems of Innovation (SI) literature (Freeman, 1987 , Lundvall, 1992 , Nelson, 1993 as a theoretical framework. Central to this concept is the idea that the overall innovation performance of an economy depends not so much on how specific organisations perform but on how well they interact with each other. Systems of innovation have been analysed at several levels ranging from sectoral and enterprise specific innovation systems, to local, national, regional and global systems of innovation.
Modern biotechnology requires a multi-sectoral approach since it's techniques are used in a number of different "biotechnology-based sectors" (Saviotti, 1998, p. 19) 12). Bartholomew (1997) was perhaps the first author to refer to a national system of biotechnology innovation which she defined as "the specific institutional arrangements within a country which affect the generation of scientific knowledge relevant to biotechnology, and the diffusion of that knowledge throughout industry".
Country specific factors in the development of the biotechnology industry have been extensively investigated often within a SI framework e.g. in Canada, Japan and Germany (Arundel and Rose, 1999 , Fransman and Tanaka, 1995 , Momma and Sharp, 1999 . Less work has been published on smaller or less developed economies with the exception of Fontes and Novais (1998) on Portugal, Rickne (1999) on Sweden and various authors (Janszen and Deganaars, 1998, van Geenhuizen, 1999) on the Netherlands.
New Zealand's National System of Innovation
New Zealanders like to think of themselves as innovative people who can fix anything with a piece of No. 8 fencing wire. This kind of innovation enabled many enterprises to develop and prosper while making do with local resources but seems to be less suited to competing in the global economy. Engelbrecht and Darroch (1999) used a range of indicators to measure innovation, knowledge absorption and diffusion and compared the performance of New Zealand with other OECD economies. New Zealand consistently scored below Australia and below the average for G7 and other small, high-income OECD countries.
New Zealand had the poorest record of all 18 countries for potential to produce knowledge.
The high level of FDI inflows and strong imports of manufactured goods mean that there should be plenty of opportunities for knowledge to flow into the country. However it had the lowest number of science graduates of the 18 sample countries and was ranked lowest on indicators of whether diffusion had actually taken place. Overall they concluded that "New Zealand continues to have a weak National Innovation System, despite the major changes to its research, science and technology sector since the late 1980s, and despite its openness to foreign direct investment". This finding is supported by another empirical investigation into the national innovative capacity of a sample of 17 OECD countries from 1973 to 1996, which found that "a .. group, including Italy, New Zealand and Spain, lags behind the rest of the OECD over the full time period" (Stern et al., 2000, p. 31 ).
The strength of New Zealand's science base is an important determinant of the effectiveness of the National Innovation System and should also provide a strong indication of the degree (if any) of New Zealand's advantage in the area of biotechnology. Cole and Phelan's (1999) investigation into the scientific productivity of nations found that New Zealand had a high output of scientific papers relative to the size of its economy. In a study of 43 countries New Zealand ranked seventh ahead of the UK, Canada, Australia the USA and Japan. Zealand papers in these areas was within 10% of the world average.
Overall, New Zealand's science base is relatively small (compared to G7 and small OECD countries) and is heavily skewed towards certain areas (e.g. biology, clinical medicine and agriculture). New Zealand scientists have a high productivity (measured by papers per scientist) but New Zealand science is not highly cited internationally except in a handful of specialist areas e.g. pharmacology.
Biotechnology in New Zealand
Despite the small size of its economy and of its science base New Zealand has had a significant role in the biotechnology revolution. New Zealand contributed to the birth of modern biotechnology through the first description of the structure of DNA by a New Zealand born Probe, ViaLactia. The government has been estimated to spend around NZ$100m a year on biotechnology-related research ranging from genomics to processing of natural products (Rolleston, 1999, p. 46) , of this around NZ$18 million is spent on research involving genetic modification (Wright, 2000, p.7) . Biotechnology-related research comprises around 17% of total spending on 'the Science Envelope' (NZ$586 million in 1999/2000, NZ$1 = US$0.42).
Genesis has invested NZ$41 million in research since its inception in 1994 while CRI's and companies such as Auckland UniServices have also been successful in generating research revenue from outside the government sector. Nonetheless it must be recognised that New
Zealand's total expenditure on biotechnology research is very small by global standards. (Ernst & Young, 1999, p. 35) .
In 2000 Statistics New Zealand undertook the first comprehensive survey on the use of biotechnology in New Zealand. The main objectives were to describe the present structure of the 'industry' in order to assist planning and to provide a baseline against which progress could be measured at a future date. The survey was sent to 426 enterprises that had been identified as possible users of a list of 54 biotechnology processes and achieved a 98% response rate with 180 respondents identified as users of at least one process. The high response rate and wide ranging methods used to identify possible users of modern biotechnology suggest that the survey is likely to have captured almost all significant users of modern biotech over the survey period (1998/99).
Respondents were divided into four categories (see Figure 1 ) based on whether they used modern or traditional processes and whether they were creators (engaged in R&D) or simply users of biotechnology processes. The term Modern Biotech Enterprise (MBE) is used to describe respondents that are engaged in R&D into at least one modern biotech process. Academics and policy makers have a particular interest in this group, since their innovative performance will be crucial in determining New Zealand's overall performance in the biotech area. Some of their key characteristics are presented as Table 1 .
( MBEs; twelve firms reported that they received all of their income from biotech and so might be referred to as dedicated biotech firms. A further 36 enterprises used modern biotech processes (but were not engaged in R&D) and employed around 950 people in 'biotech based activities', which provided income of NZ$112 million.
The Statistics New Zealand biotech survey was closely modelled on work carried out by Statistics Canada thus enabling some comparisons to be made. However there are some important differences; the New Zealand definition of biotech included several additional processes and so was somewhat wider than that used in Canada; the number of biotech firms is also not directly comparable since the Canadian survey excluded firms that had less than five employees and less than C$100,000 R&D expenditure.
An approximate comparison between the two data sets is included as 
Data from Patenting
The use of data from patenting as an indicator of innovative activity has been well established for many years. There is also a rapidly increasing literature in the biotechnology area based on analysis of patents (Foltz et al., 2000 , Joly and de Looze, 1996 , Malo and Geuna, 1999 , McMillan et al., 2000 .
Analysis of New Zealand patenting activity in biotechnology was carried out using international applications published in the Patent Cooperation Treaty (PCT) Electronic Gazette. The PCT provides for the filing of an international application to have the same effect as a national application in each of the contracted states designated in the application (OECD, 1994, p. 19) ;
it thus provides a useful measure of international patenting activity. Use of applications data provides a more immediate picture, since it can take up to five years from the first application for a patent to be granted.
Methodology based on Engelbrecht and Darroch (1999) was used to compare New
Zealand's rate of patenting with G7 and a reference group of small high-income OECD countries (see Table 3 ). For the purposes of this analysis modern biotechnology was taken to be synonymous with the International Patent Class C12N, while a 'Broad Definition' of biotechnology included a number of other classes detailed below 2 .
( HortResearch was reported to be 3-5% per annum "there were limited cross-CRI transfers and just a few people moving on to universities or polytechnics" (Clark et al., 1999, p. 6 ).
Some private firms placed little emphasis on linkages in development of biotechnology innovation; others found few organisations worth linking with (perhaps because the use of modern biotechnology in New Zealand is so limited) and so concentrated on developing strategic alliances and joint ventures with overseas partners. Others felt that CRI's and universities have little to offer them: "they operate on a completely different time horizon … the difference between commercial reality and university and government research is so wide that most people cannot understand that what they are doing never actually achieves a desired outcome" (interview C).
This view is supported by another biotech CEO quoted in Mazoyer (1999) : "NZ does not have a broad range of public research agencies that are well inter-linked. There may not be much cross-over into industry -in fact the public research system seems to operate in a sector of its own". Opinion is divided as to whether it is the public research agencies which don't meet the needs of the private sector or the private sector which has a limited ability to apply the results of publicly funded R&D or to evaluate opportunities (Winsley et al., 1998, p. 
61). It is not surprising then, that Mazoyer goes on to conclude that "commercialisation is sometimes
hindered by a lack of interaction between the science sector and manufacturers … [and that] more effective learning interactions and networking between scientists, public and private investors and users need to be encouraged" (1999, pp. 6-7).
Modern biotechnology activity in New Zealand may perhaps be better described through the idea of 'islands of excellence'. Leading edge work is carried out in a number of areas; but these islands of excellence tend to collaborate strongly with a small number of other organisations rather than being strongly connected to any wider innovation system. A good example is provided by the forestry industry where a small number of leading companies collaborated with the Forest Research Institute to promote research into forest biotechnology.
A New Zealand company was able to develop the ability to genetically transform pine trees using a company scientist, a recent graduate with an MSc in biotechnology and email contact with a colleague in Canada (interview D). This is now an area where New Zealand based firms and scientists are at the forefront of technology. Arborgen the world's leading forestry biotechnology company is a joint venture between two huge US companies (International Paper and Westvaco Corporation) and three New Zealand companies (Fletcher Challenge
Forests, Genesis and Carter Holt Harvey).
Similarly Genesis was founded using intellectual property from the University of Auckland and has strong partnerships with two CRI's, the New Zealand Dairy Board and six overseas companies. However Genesis can probably be best characterised as being part of the international innovation system for biotechnology rather than having particularly strong links with many New Zealand based institutions.
Framework Conditions for Innovation
Many of those interviewed for this study had serious concerns about New Zealand's framework conditions for innovation. They focussed particularly on "the lack of a pro-business environment, national attitudes to entrepreneurs and risk takers and the regulatory framework which has made New Zealand an expensive country in which to do business". One interviewee cited the recent increase in the top rate of income tax as an example of negative attitudes to business that has harmed their ability to recruit scientists internationally. He also expressed the opinion that "we don't like people being enterprising, we don't admire people being rich
[and]… if we don't have an admiration for people taking risks and being successful then we won't have innovation in biotechnology.
Increasing levels of popular concern over the safety of some modern biotechnologies Unfortunately these low research costs are a double-edged sword when it comes to attracting overseas talent and retaining top New Zealand scientists as illustrated by the following quote from a CRI manager: "We were recruiting a plant breeder. We had a very good candidate from the US who we brought out here. We paid for him to come out. We said we don't want you to come just for an interview, come for a week. You need to find out about us and we need to find out about you. He was our preferred candidate. We offered him between $5,000 -$10,000 more per annum starting salary. So we really wanted this person. But he converted his dollars back and said 'No'" (Clark et al., 1999, p. 5) .
Government Policy
Over the six years from 1984 to 1991 New Zealand engaged in "one of the most radical market liberalisation programmes initiated anywhere in the world" (Massey, 1995, p. xii The document goes on to describe "principles and behaviours to be encouraged" which include: the need for a targeted, rapid and flexible investment system by Government; the development of an entrepreneurial spirit; partnerships and linkages between stakeholders;
increased global linkages to exploit New Zealand's competitive advantage; and enhanced integration and leadership among sector groups and along value chains.
New Zealand's approach has contrasted strongly with some of its regional trading partners. In Australia, the federal government established two new agencies "to ensure Australia realises the potential gains being offered by biotechnology" (Biotechnology Australia, 2000) . The
Singapore Government has a strategy 'to position Singapore as the strategic hub for the pharmaceutical, biotechnology and health care industry in Asia' while Taiwan aims to develop into 'an Asia-Pacific R&D Center' and 'an Asia-Pacific Manufacturing Center for high-tech products'. Taiwan currently spends NZ$200 million per year on biotech and is increasing its technology budget by 10-15% per year (Rolleston, 1999, p. 43 ).
There is a significant level of dissatisfaction with government policy towards research, science and technology in New Zealand. Indeed Sommer (2001, p. 7) More specific criticisms are that "the science reforms produced an over-emphasis on incremental innovation or technology and undermined the science base, leaving less time for research from which big new ideas could emerge" (quoted in Mazoyer, 1999, p. 9) ; and a "focus on small projects focussed on individuals has taken away the ability of CRI's to build future science capabilities"(interview A). This is supported by Petersen (1998, p. 10) who suggests "there must be some mechanism that allows scientist to be kept on the payroll while alternative funding routes are worked out". There is a serious brain drain of students completing PhD's "because they are not prepared to spend the rest of their lives living from hand to mouth on short-term contracts".
On a more positive note some interviewees found that government programmes to encourage technology transfer were useful. They attributed low uptake of these programmes to company culture and short termism. Others said accountability requirements were excessive (Mazoyer, 1999, p. 10) .
R&D Funding
It has been known for some years that New Zealand's expenditure on R&D is low relative to other OECD members. In 1996 New Zealand's gross expenditure on R&D (GERD) was 0.98% compared to 2% or over for G7 and a group of small OECD countries (Engelbrecht and Darroch, 1999) . Spending by New Zealand industry, as a % of GDP was 0.26% in 1995, far below the OECD average of 1.46% (OECD, 1999, p. 131) . While no comprehensive data is available on R&D expenditure on biotechnology, it may be logical to assume that "if New
Zealand is bad at doing R&D generally it would [expect to be] a whole lot worse in the biotech area" (interview B).
One factor that would be expected to affect the level of R&D expenditure by industry is the tax and incentive regime. In a recent review of the evidence on the effects of fiscal incentives for It has also been suggested that differences in national tax regimes may significantly bias reported levels of R&D expenditure. The negative treatment of such expenditures in New
Zealand encourages under-reporting while the favourable treatment in other countries encourages widespread over-reporting.
Industry views appear to be somewhat polarised on whether the tax treatment of R&D spending has had a major effect on the level of expenditure in the private sector. Some large players saw this as a key influence: "the 150% tax rebate meant that you could do research for free in Australia and make money out of it … it was a pretty favourable regime -nothing like that here" (interview B). Others were more sceptical: "I have not seen results that suggest support of R&D delivers real commercial benefits" (interview C).
Difficulties in obtaining venture capital may also constrain start-up or expanding biotech firms in New Zealand, although some suggest "the lack of entrepreneurs who can build companies, rather than a shortage of money, is curtailing the development of new companies" (Springall, 2000 
Conclusions
New Zealand has some 'islands of excellence' where world-leading biotechnology R&D is carried out and despite its small size has played a significant role in the biotechnology revolution. While most biotech activities build on existing strengths in primary industry (e.g. Zealand's rate of modern biotech patent applications is below average for the G7 and for a reference group of small developed OECD economies. New Zealand's biotech revenue per million population (NZ$54 million) is rather lower than Canada's (NZ$94 million), but the difference is fairly small considering Canada's higher per capita income and proximity to the United States.
The factors that seem to have encouraged the emergence of world-leading research are diverse ranging from strong basic science in medical research and science push in sheep genomics, to industry pull in the case of forest biotechnology. Growth in these and other biotech-based sectors may be constrained by the poor performance of New Zealand's National System of Innovation. The system is dominated by Crown Research Institutes and universities which rely on government for the majority of their funding. Leading edge work is carried out in certain areas, but this tends to involve links with a small number of organisations rather than strong connections to any wider system of innovation. There have been major changes to research, science and technology policy since the late 80's, but it remains to be seen whether these will result in improved performance.
The New Zealand Government has not taken leadership in fostering innovation in modern biotechnology. Indeed government and industry only seem to have taken a close interest in biotechnology i n the last four to five years. New Zealand has not made the kinds of large investment seen in Australia and some of its regional trading partners. Instead it has concentrated on science sector reforms and a free market oriented approach. New Zealand
has the potential to demonstrate a new model for the development of a biotech industry based on comparative advantage in primary industry and some other niche areas. The jury is still out on whether New Zealand's innovation environment will allow that potential to be achieved. 
